Detection and treatment of polycystic kidney disease

Abstract

Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods of treating a subject having a PKD1-associated disorder.

What is claimed is: 
     
         1 . A method of selectively amplifying a region of the PKD1 gene, but not the corresponding region of a PKD1 homolog, wherein said PKD1 gene comprises SEQ ID NO:1, the method comprising amplifying a DNA sample which contains the PKD1 gene with a set of eight PKD1-specific primer pairs to obtain PKD1-specific amplification products of the PKD1 gene, wherein the amplification products do not contain PKD1 homolog sequence. 
     
     
         2 . The method of  claim 1 , wherein said set of eight primer pairs selectively hybridize to SEQ ID NO:1 and amplify portions of SEQ ID NO:1 comprising about nucleotides 2043 to 4290; nucleotides 17907 to 22489; nucleotides 22218 to 26363; nucleotides 26246 to 30615; nucleotides 30606 to 33957; nucleotides 36819 to 37140; nucleotides 37329 to 41258 and nucleotides 41508 to 47320. 
     
     
         3 . The method of  claim 2 , wherein said set of eight primer pairs comprise SEQ ID NOS:3 and 4; SEQ ID NOS:5 and 6; SEQ ID NOS:7 and 8; SEQ ID NOS:9 and 10; SEQ ID NOS:11 and 12; SEQ ID NOS:13 and 14; SEQ ID NOS:15 and 16; and SEQ ID NOS:17 and 18. 
     
     
         4 . The method of  claim 1 , wherein said PKD1-specific amplification products encompass all of the exons within the PKD1 gene. 
     
     
         5 . The method of  claim 1 , further comprising performing a nested PCR reaction comprising contacting the PKD1-specific amplification products of claim  79  with a second set of primers under conditions suitable for nested PCR to obtain nested PCR products of the PKD1-specific amplification products. 
     
     
         6 . The method of  claim 5 , wherein the second primer pair is selected from the group consisting of SEQ ID NOS:19 and 20; SEQ ID NOS:21 and 22; SEQ ID NOS:23 and 24; SEQ ID NOS:25 and 26; SEQ ID NOS:27 and 28; SEQ ID NOS:29 and 30; SEQ ID NOS:31 and 32; SEQ ID NOS:33 and 34; SEQ ID NOS:35 and 36; SEQ ID NOS:37 and 38; SEQ ID NOS:39 and 40; SEQ ID NOS:41 AND 42; SEQ ID NOS:43 and 44; SEQ ID NOS:45 and 46; SEQ ID NOS:47 and 48; SEQ ID NOS:49 and 50; SEQ ID NOS:51 and 61; primer pairs formed using consecutive primers set forth in Table 2 as SEQ ID NOS:62 to 96, 113, and 97 to 112; or any combination of pairs thereof. 
     
     
         7 . The method of  claim 5 , further comprising a dilution step, to remove genomic contamination from the amplification products, prior to the nested PCR reaction. 
     
     
         8 . The method of  claim 1 , wherein the nucleotide sequences of the PKD1-specific amplification products obtained from a patient sample are compared to the nucleotide sequence of PKD1-specific amplification products from a control sample to determine if there are one or more differences between the PKD1-specific amplification products of the patient sample and the control sample, wherein the presence of one or more differences in the sequence of the PKD1-specific amplification products in the patient sample compared to the control sample PKD1 sequence is indicative of a mutation in the patient's PKD1 gene. 
     
     
         9 . The method of  claim 8 , wherein the one or more differences are selected from the group consisting of:
 nucleotide 474, wherein nucleotide 474 is a T;   nucleotide 487, wherein nucleotide 487 is an A;   nucleotide 3110, wherein nucleotide 3110 is a C;   a position corresponding to nucleotide 3336, wherein nucleotide 3336 is deleted;   nucleotide 3707, wherein nucleotide 3707 is an A;   nucleotide 4168, wherein nucleotide 4168 is a T;   nucleotide 4885, wherein nucleotide 4885 is an A;   nucleotide 5168, wherein nucleotide 5168 is a T;   nucleotide 6058, wherein nucleotide 6058 is a T;   nucleotide 6078, wherein nucleotide 6078 is an A;   nucleotide 6089, wherein nucleotide 6089 is a T;   nucleotide 6195, wherein nucleotide 6195 is an A;   nucleotide 6326, wherein nucleotide 6326 is a T;   a position corresponding to nucleotides 7205-7211, wherein nucleotides 7205 to 7211 are deleted;   nucleotide 7376, wherein nucleotide 7376 is a C;   a nucleotide sequence corresponding to nucleotides 7535 to 7536, wherein a GCG nucleotide sequence is inserted between nucleotides 7535 and 7536;   nucleotide 7415, wherein nucleotide 7415 is a T;   nucleotide 7433, wherein nucleotide 7433 is a T;   nucleotide 7696, wherein nucleotide 7696 is a T;   nucleotide 7883, wherein nucleotide 7883 is a T;   nucleotide 8021, wherein nucleotide 8021 is an A;   a nucleotide sequence corresponding to nucleotide 8159 to 8160, wherein nucleotides 8159-8160 are deleted;   nucleotide 8298, wherein nucleotide 8298 is a G;   nucleotide 9164, wherein nucleotide 9164 is a G;   nucleotide 9213, wherein nucleotide 9213 is an A;   nucleotide 9326, wherein nucleotide 9326 is a T;   nucleotide 9367, wherein nucleotide 9367 is a T;   nucleotide 10064, wherein nucleotide 10064 is an A;   nucleotide 10143, wherein nucleotide 10143 is a G;   nucleotide 10234, wherein nucleotide 10234 is a C;   nucleotide 10255, wherein nucleotide 10255 is a T;   or a combination thereof.   
     
     
         10 . The method of  claim 5 , wherein the nucleotide sequence of the nested PCR products of the PKD1-specific amplification products obtained from a patient sample are compared to the nucleotide sequence of the nested PCR products of the PKD1-specific amplification products from a control sample to determine if there are one or more differences between the nucleotide sequence of the nested PCR products of the patient sample and the control sample, wherein the presence of one or more differences in the nucleotide sequence of the nested PCR products in the patient sample compared to the nucleotide sequence of the nested PCR products in the control sample is indicative of a mutation in the patient's PKD1 gene. 
     
     
         11 . The method of  claim 10 , wherein the one or more differences are selected from the group consisting of:
 nucleotide 474, wherein nucleotide 474 is a T;   nucleotide 487, wherein nucleotide 487 is an A;   nucleotide 3110, wherein nucleotide 3110 is a C;   a position corresponding to nucleotide 3336, wherein nucleotide 3336 is deleted;   nucleotide 3707, wherein nucleotide 3707 is an A;   nucleotide 4168, wherein nucleotide 4168 is a T;   nucleotide 4885, wherein nucleotide 4885 is an A;   nucleotide 5168, wherein nucleotide 5168 is a T;   nucleotide 6058, wherein nucleotide 6058 is a T;   nucleotide 6078, wherein nucleotide 6078 is an A;   nucleotide 6089, wherein nucleotide 6089 is a T;   nucleotide 6195, wherein nucleotide 6195 is an A;   nucleotide 6326, wherein nucleotide 6326 is a T;   a position corresponding to nucleotides 7205-7211, wherein nucleotides 7205 to 7211 are deleted;   nucleotide 7376, wherein nucleotide 7376 is a C;   a nucleotide sequence corresponding to nucleotides 7535 to 7536, wherein a GCG nucleotide sequence is inserted between nucleotides 7535 and 7536;   nucleotide 7415, wherein nucleotide 7415 is a T;   nucleotide 7433, wherein nucleotide 7433 is a T;   nucleotide 7696, wherein nucleotide 7696 is a T;   nucleotide 7883, wherein nucleotide 7883 is a T;   nucleotide 8021, wherein nucleotide 8021 is an A;   a nucleotide sequence corresponding to nucleotide 8159 to 8160, wherein nucleotides 8159-8160 are deleted;   nucleotide 8298, wherein nucleotide 8298 is a G;   nucleotide 9164, wherein nucleotide 9164 is a G;   nucleotide 9213, wherein nucleotide 9213 is an A;   nucleotide 9326, wherein nucleotide 9326 is a T;   nucleotide 9367, wherein nucleotide 9367 is a T;   nucleotide 10064, wherein nucleotide 10064 is an A;   nucleotide 10143, wherein nucleotide 10143 is a G;   nucleotide 10234, wherein nucleotide 10234 is a C;   nucleotide 10255, wherein nucleotide 10255 is a T;   or a combination thereof.   
     
     
         12 . The method of  claim 6 , wherein the sequences of the PKD1-specific amplification products obtained from a patient sample are compared to the sequence of PKD1-specific amplification products from a control sample to determine if there are one or more differences between the PKD1-specific amplification products of the patient sample and the control sample, and wherein the presence of one or more differences in the sequence of the PKD1-specific amplification products compared to the control PKD1 sequence is indicative of a mutation in the PKD1 gene. 
     
     
         13 . The method of  claim 12 , wherein the one or more differences are selected from the group consisting of:
 nucleotide 474, wherein nucleotide 474 is a T;   nucleotide 487, wherein nucleotide 487 is an A;   nucleotide 3110, wherein nucleotide 3110 is a C;   a position corresponding to nucleotide 3336, wherein nucleotide 3336 is deleted;   nucleotide 3707, wherein nucleotide 3707 is an A;   nucleotide 4168, wherein nucleotide 4168 is a T;   nucleotide 4885, wherein nucleotide 4885 is an A;   nucleotide 5168, wherein nucleotide 5168 is a T;   nucleotide 6058, wherein nucleotide 6058 is a T;   nucleotide 6078, wherein nucleotide 6078 is an A;   nucleotide 6089, wherein nucleotide 6089 is a T;   nucleotide 6195, wherein nucleotide 6195 is an A;   nucleotide 6326, wherein nucleotide 6326 is a T;   a position corresponding to nucleotides 7205-7211, wherein nucleotides 7205 to 7211 are deleted;   nucleotide 7376, wherein nucleotide 7376 is a C;   a nucleotide sequence corresponding to nucleotides 7535 to 7536, wherein a GCG nucleotide sequence is inserted between nucleotides 7535 and 7536;   nucleotide 7415, wherein nucleotide 7415 is a T;   nucleotide 7433, wherein nucleotide 7433 is a T;   nucleotide 7696, wherein nucleotide 7696 is a T;   nucleotide 7883, wherein nucleotide 7883 is a T;   nucleotide 8021, wherein nucleotide 8021 is an A;   a nucleotide sequence corresponding to nucleotide 8159 to 8160, wherein nucleotides 8159-8160 are deleted;   nucleotide 8298, wherein nucleotide 8298 is a G;   nucleotide 9164, wherein nucleotide 9164 is a G;   nucleotide 9213, wherein nucleotide 9213 is an A;   nucleotide 9326, wherein nucleotide 9326 is a T;   nucleotide 9367, wherein nucleotide 9367 is a T;   nucleotide 10064, wherein nucleotide 10064 is an A;   nucleotide 10143, wherein nucleotide 10143 is a G;   nucleotide 10234, wherein nucleotide 10234 is a C;   nucleotide 10255, wherein nucleotide 10255 is a T;   or a combination thereof.   
     
     
         14 . A method of detecting mutations in a PKD1 gene comprising SEQ ID NO:1, comprising the steps of:
 amplifying genomic DNA contained in test and control samples with a set of eight PKD1-specific primer pairs to obtain PKD1-specific amplification products of the PKD1 gene;   diluting the PKD1-specific amplification products to remove genomic contamination from the amplification products;   contacting the diluted amplification products with a second set of primers under conditions suitable for nested PCR to obtain nested PCR products of the PKD1-specific amplification products; and   comparing the nucleotide sequence of the nested PCR products in the test sample with the nucleotide sequence of the nested PCR products in the control sample, whereby the presence of one or more differences in the nucleotide sequence of the nested PCR products of the test sample compared to the nucleotide sequence of the nested PCR products of the control sample is indicative of a mutation in the PKD1 gene.   
     
     
         15 . The method of  claim 14 , wherein the one or more mutations are selected from the group consisting of:
 nucleotide 474, wherein nucleotide 474 is a T;   nucleotide 487, wherein nucleotide 487 is an A;   nucleotide 3110, wherein nucleotide 3110 is a C;   a position corresponding to nucleotide 3336, wherein nucleotide 3336 is deleted;   nucleotide 3707, wherein nucleotide 3707 is an A;   nucleotide 4168, wherein nucleotide 4168 is a T;   nucleotide 4885, wherein nucleotide 4885 is an A;   nucleotide 5168, wherein nucleotide 5168 is a T;   nucleotide 6058, wherein nucleotide 6058 is a T;   nucleotide 6078, wherein nucleotide 6078 is an A;   nucleotide 6089, wherein nucleotide 6089 is a T;   nucleotide 6195, wherein nucleotide 6195 is an A;   nucleotide 6326, wherein nucleotide 6326 is a T;   a position corresponding to nucleotides 7205-7211, wherein nucleotides 7205 to 7211 are deleted;   nucleotide 7376, wherein nucleotide 7376 is a C;   a nucleotide sequence corresponding to nucleotides 7535 to 7536, wherein a GCG nucleotide sequence is inserted between nucleotides 7535 and 7536;   nucleotide 7415, wherein nucleotide 7415 is a T;   nucleotide 7433, wherein nucleotide 7433 is a T;   nucleotide 7696, wherein nucleotide 7696 is a T;   nucleotide 7883, wherein nucleotide 7883 is a T;   nucleotide 8021, wherein nucleotide 8021 is an A;   a nucleotide sequence corresponding to nucleotide 8159 to 8160, wherein nucleotides 8159-8160 are deleted;   nucleotide 8298, wherein nucleotide 8298 is a G;   nucleotide 9164, wherein nucleotide 9164 is a G;   nucleotide 9213, wherein nucleotide 9213 is an A;   nucleotide 9326, wherein nucleotide 9326 is a T;   nucleotide 9367, wherein nucleotide 9367 is a T;   nucleotide 10064, wherein nucleotide 10064 is an A;   nucleotide 10143, wherein nucleotide 10143 is a G;   nucleotide 10234, wherein nucleotide 10234 is a C;   nucleotide 10255, wherein nucleotide 10255 is a T;   or a combination thereof.